Here's a clear breakdown of Skye Bioscience's PRE 14A filing:

🧾 What This Document Is

This is a preliminary proxy statement for Skye Bioscience's 2026 Annual Shareholder Meeting. It outlines proposals shareholders will vote on and provides essential company information. Think of it as the agenda and background packet for the meeting.

🏢 What The Company Does

👉 In simple terms: Skye Bioscience is a biotech company developing new drugs for metabolic diseases, focusing on obesity. Their lead drug candidate is nimacimab, which works by blocking a receptor (CB1) outside the brain to help improve weight loss when combined with existing drugs like semaglutide (Ozempic/Wegovy).

📅 Key Meeting Details

• Format: Virtual-only meeting via webcast.
• Record Date: Shareholders as of the close of business on [DATE TBD] can vote.
• Date & Time: [DATE TBD] at 10:00 a.m. Pacific Time.
• Access: www.virtualshareholdermeeting.com/SKYE2026 (requires Control Number from proxy materials).

🗳️ What Shareholders Are Voting On (Proposals)

The Board recommends voting FOR all proposals:

1. Proposal 1: Elect Directors

   • Vote for 6 nominees: Paul Grayson (Chair), Deborah Charych, Punit Dhillon (CEO), Annalisa Jenkins, Karen Smith, Andrew J. Schwab.
   • Why it matters: Sets the leadership team guiding the company's strategy and overseeing management. Their diverse biotech experience is crucial for drug development.
   • Vote Required: Plurality (most "For" votes win).

2. Proposal 2: Ratify Auditor

   • Approve CBIZ CPAs P.C. as the independent accounting firm for 2026.
   • Why it matters: Standard governance ensuring an independent review of the company's finances. CBIZ replaced Marcum LLP in 2025 after Marcum's attest business was acquired.
   • Vote Required: More "For" than "Against" votes.

3. Proposal 3: Increase Authorized Shares

   • Amend the company's Articles to increase authorized common stock from 100,000,000 to 300,000,000 shares.
   • Why it matters (⚠️ Critical): Provides flexibility for future financing (like selling shares to raise cash), acquisitions, or stock-based compensation. However, it significantly increases potential dilution for existing shareholders. The board needs this to fund ongoing clinical trials.
   • Vote Required: Majority of outstanding shares entitled to vote (Abstentions/Broker Non-Votes count as "Against").

4. Proposal 4: Advisory Vote on Executive Compensation ("Say-on-Pay")

   • Approve the compensation of named executive officers (like CEO Punit Dhillon).
   • Why it matters: A non-binding vote expressing shareholder sentiment on whether executive pay aligns with company performance. It's advisory but influential.
   • Vote Required: More "For" than "Against" votes.

👥 Board of Directors & Governance

• Size: 6 directors.
• Independence: 4 of 6 directors are independent (Grayson, Charych, Jenkins, Smith). Dhillon (CEO) and Schwab (5AM Ventures affiliate) are not.
• Committees: Audit (Jenkins-Chair, Smith, Grayson), Compensation (Smith-Chair, Jenkins, Grayson), Nominating & Governance (Charych-Chair, Smith, Jenkins, Grayson). All committees are fully independent.
• Leadership: Separated - Paul Grayson is Chairman, Punit Dhillon is CEO.
• Key Policies: Anti-hedging, Clawback Policy (recoup compensation after accounting restatements), Insider Trading Policy.

💼 Executive Compensation Highlights

• CEO Pay (2025): Punit Dhillon received a total compensation of $1,130,344 (Salary: $400k, Bonus: $230k, Option Awards: $500,344).
• Other NEOs: Compensation details for other named executive officers are included (see full proxy).
• Director Pay (2025): Non-employee directors received annual cash retainers ($37.5k-$91.875k depending on roles) and annual option grants (35k shares). Total comp ranged from ~$109k to ~$369k.

🧪 Clinical Progress Update (CEO Letter Context)

• Nimacimab in Obesity: Positive Phase 1b data (CBeyond™ study) showed nimacimab + semaglutide led to 22.3% mean weight loss at 52 weeks vs. semaglutide alone, with good tolerability and no plateau observed.
• Key Learning: Monotherapy dose was likely too low; initiating a higher-dose expansion study.
• Next Steps: Preparing for Phase 2b trial design, advancing formulation & delivery (working with Halozyme), and expanding platform (early antibody-peptide conjugate data).

⚖️ Big Picture: Strengths & Risks

• 👍 Strengths:
  • Differentiated obesity drug mechanism (peripheral CB1 blockade).
  • Promising combination data showing enhanced weight loss.
  • Experienced board with deep biotech expertise.
  • Clear development path towards Phase 2b.
• ⚠️ Risks:
  • Significant Dilution Threat (Proposal 3): Tripling authorized shares could substantially dilute existing shareholders if all shares are issued.
  • Clinical development risk (Phase 2b success not guaranteed).
  • Dependence on partnership with Halozyme for delivery tech.
  • Operating losses; need to secure future funding (linked to Proposal 3).

🧠 The Analogy

Skye is like a construction crew building a crucial bridge (a new obesity drug) over a fast river (the competitive obesity drug market). The crew (Board) needs more materials (Authorized Shares - Proposal 3) to build a stronger, higher bridge (Phase 2b trial) that can handle heavier traffic (more effective treatment). Shareholders are being asked to approve the extra materials (dilution risk), trusting the experienced crew's plan that this bridge design (peripheral CB1 blockade combo) will be safer and better than others being built.

🧩 Final Takeaway

Shareholders must decide whether to re-elect the experienced board, approve auditors, and endorse executive pay. The critical vote is on tripling authorized shares, framing it as necessary fuel for the promising but capital-intensive obesity drug development engine, while accepting the risk of significant ownership dilution. The CEO letter strongly advocates for this strategy based on early clinical success.